Agenus Inc AGEN:NASDAQ

Agenus (AGEN) said Monday that data from a 70-patient group in a Phase 1b study of botensilimab combined with balstilimab to treat colorectal cancer showed the combination "offers superior efficacy and durability" compared with standard of care and other investigational treatments.

The company said it saw an overall response rate of 23% and a disease control rate of 76% in the cohort.

Agenus said the 12-month overall survival was 63% and the median overall survival hasn't been reached.

The company said Phase 2 trials of the combination to treat colorectal cancer and other diseases have started and it expects to begin a Phase 3 colorectal cancer study this year.

Agenus shares were down over 7% in recent trading.

Price: 2.53, Change: -0.17, Percent Change: -6.48